| F |
|
FACTOR (F)XA STIMULATES FIBROPROLIFERATIVE RESPONSES IN FIBROBLASTS VIA PROTEASE ACTIVATED RECEPTOR (PAR)-2 ACTIVATION: IMPLICATIONS FOR TISSUE REMODELING
|
| Borensztajn K.S., Stiekema J., Monti M., Reitsma P.H., Peppelenbosch M.P., Spek C.A. |
| |
|
FACTOR IX CONCENTRATED IN THE JOINT SPACE PROTECTS HEMOPHILIA B MICE FROM BLEEDING-INDUCED JOINT DETERIORATION IN THE ABSENCE OF CIRCULATING FACTOR IX
|
| Sun J., Hakobyan N., Valentino L.A., Monahan P.E. |
| |
|
FACTOR IX GENE VARIANTS AND THE RISK OF VENOUS THROMBOSIS
|
| van Minkelen R., Poort S.R., van Hylckama Vlieg A., de Visser M.C.H., Vos H.L., Rosendaal F.R., Bertina R.M. |
| |
|
FACTOR IX MALM IS ASSOCIATED WITH VENOUS THROMBOSIS
|
| Bare L.A., Bezemer I.D., Arellano A.R., Young B.A., Doggen C.J.M., Reitsma P.H., Rosendaal F.R. |
| |
|
FACTOR V AND THROMBIN INHIBITORS IN CHILDREN FOLLOWING BOVINE THROMBIN EXPOSURE
|
| Bomgaars L., West A., Fraser C., Teruya J. |
| |
|
FACTOR V DEFICIENCY DUE TO A NOVEL HOMOZYGOUS MUTATION: FV N468S, BUT NO BLEEDING TENDENCY
|
| Shinozawa K., Amano K., Takamiya O., Shiozaki N., Ando T., Seita I., Ogata K., Suzuki T., Inaba H., Fukutake K. |
| |
|
FACTOR V INHIBITORS: DIVERSITY IN CLINICAL PRESENTATION
|
| Gadelha T., Aquino J.W., Assunção E., Santos F.L., Oliveira M.F.H.C. |
| |
|
FACTOR V IS AN INDEPENDENT PREDICTOR OF MORTALITY IN PATIENTS WITH CIRRHOSIS: USEFUL TOOL IN PATIENTS WAITING FOR LIVER TRANSPLANTATION
|
| Martinuzzo M.E., Ruf A., Cerrato G.S., Chavez L., Perez Lloret S., Cairo F., Gruz F., Fuxman C., Descalzi V., Podestá G., Villamil F., Forastiero R.R. |
| |
|
FACTOR V LEIDEN (FVL) AND PROTHROMBIN GENE VARIANT (PGV) MAY BE ONLY WEAKLY ASSOCIATED WITH PLACENTA MEDIATED PREGNANCY COMPLICATIONS: A LARGE PROSPECTIVE COHORT STUDY
|
| Rodger M.A., Walker M.C., Wu Wen S., Smith G., Carson N., Gin B., Wells P.S. |
| |
|
FACTOR V LEIDEN (G1691A) AND PROTHROMBIN (G20210A) GENOTYPING BY HIGH-RESOLUTION MELT ANALYSIS (HRM) AND SYTO 9 FLUORESCENT DYE ON THE ROTOR-GENE 6000 HRM
|
| Ameziane N., Lamoril J., Bogard M., Kaiser T., Bouizegarene P., Guiet P., Erba G., Trichet C., Gourlin N., Herve C. |
| |
|
FACTOR V LEIDEN (G1691A), PROTHROMBIN (G20210A) AND METILENETETRAHYDROFOLATE
|
| Sabino A.P., Carvalho M.G., Ribeiro D.D., Domingheti C.P., Paiva S.G., Dusse L.M.S., Fernandes A.P.S.M. |
| |
|
FACTOR V LEIDEN AND PLACENTAL PATHOLOGY
|
| Procházka M., Laurini R., Mar[scaron]ál K., Procházková J., Lindqvist P.G. |
| |
|
FACTOR V LEIDEN AS A THROMBOPHILIA'S MARKER IN LIVER TRANSPLANTATION - AN EVALUATION
|
| Campos M.M., Santos I.R., Ribeiro M.E., Lorga A.R., Cordeiro A.L. |
| |
|
FACTOR V LEIDEN IS ASSOCIATED WITH MORE DISTAL LOCATION OF DEEP VEIN THROMBOSIS OF THE LEG
|
| Huisman M.V., Klok F.A., Karami Djurabi R., Tormene D., Simioni P., Prandoni P. |
| |
|
FACTOR V LEIDEN MUTATION AND TROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) POLYMORPHISMS ARE MILD GENETIC MODIFIERS OF HEMORRHAGIC PHENOTYPE IN HEMOPHILIA
|
| Chambost H., Morange P.E., Rothschild C., Doncarli A., Saut N., Goudemand J., Guérois C., Gerdil C., Costagliola D., Juhan-Vague I., Calvez T. |
| |
|
FACTOR V LEIDEN PROTECTS AGAINST DIABETIC NEPHROPATHY IN MICE
|
| Isermann B., Vinnikov I., Hummel B., Madhusudhan T., Kashif M., Herzog S., Bierhaus A., Nawroth P.P. |
| |
|
FACTOR V MUTATIONS IN IRANIAN PATIENTS WITH ACTIVATED PROTEIN C RESISTANCE AND VENOUS THROMBOSIS
|
| Chegeni R., Kazemi B., Hajifathali A., Pourfathollah A., Rastegarlari G. |
| |
|
FACTOR V MUTATIONS, SER234LEU AND ARG413CYS, ARE ASSOCIATED WITH FACTOR V DEFICIENCY AND A BLEEDING TENDENCY
|
| Wang X., Jin P., Ding Q., Wang H. |
| |
|
FACTOR V REMOVAL FROM BOVINE THROMBIN USED AS A TOPICAL HEMOSTAT IN SURGERY: IMPROVED PURITY THROUGH A NEW MANUFACTURING PROCESS
|
| Terrab A., Pawlak D., Hoppensteadt D., Fareed J. |
| |
|
FACTOR VA BOUND TO STORAGE INDUCED MICROPARTICLES HAVE REDUCED APC CATALYZED INACTIVATION
|
| Curvers J., Magdeleyns E.E.J.P., Keuren J.J.F.W. |
| |
|
FACTOR VII ACTIVATING PROTEASE (FSAP)
|
| Preissner K.T., Wygrecka M., Muhl L., Kanse S.M. |
| |
|
FACTOR VII ACTIVATING PROTEASE (FSAP) REGULATES CELL ADHESION AND MOTILITY BY MULTIPLE MECHANISMS
|
| Kanse S.M., Soto-Ribeiro M., Preissner K.T., Wehrle-Haller B. |
| |
|
FACTOR VII ACTIVATING PROTEASE INHIBITS THE UROKINASE PLASMINOGEN ACTIVATION SYSTEM AND STIMULATES GELATINASES (MATRIX METALLOPROTEINASES-2 AND -9) IN VASCULAR SMOOTH MUSCLE AND ENDOTHELIAL CELLS
|
| Kanse S.M., Uslu O., Hersemeyer K., Muhl L., Daniel J., Preissner K.T., Sedding D. |
| |
|
FACTOR VII ACTIVATING PROTEASE INHIBITS VASCULAR ENDOTHELIAL GROWTH FACTOR-MEDIATED PROGENITOR CELL HOMING AND DIFFERENTIATION INTO ENDOTHELIAL CELLS
|
| Rentala S., Uslu O., Muhl L., Preissner K.T., Kanse S.M. |
| |
|
FACTOR VII GENOTYPE AND CLINICAL PROFILE IN 6 IRANIAN PATIENTS WITH CONGENITAL FACTOR VII DEFICIENCY
|
| Tabatabaey A., Ravanbod S., Baghaipour M., Enayat M., Ala F., Rastegar-lari G. |
| |
|
FACTOR VIIA-ANTITHROMBIN COMPLEXES IN HUMAN PLASMA
|
| Smith S.A., Antonaci F.C., Woodhams B.J., Morrissey J.H. |
| |
|
FACTOR VIII (F8) GENE MUTATIONS AND IMMUNE TOLERANCE INDUCTION (ITI) IN HAEMOPHILIA A WITH INHIBITORS: DATA FROM THE ITALIAN ITI REGISTRY (THE PROFIT STUDY)
|
| Margaglione M., Grandone E., Castaman G., Morfini M., Zanon E., Tagariello G., Coppola A., Iannaccaro P., Mancuso G., Di Minno G. |
| |
|
FACTOR VIII A2 DOMAIN INTERACTION WITH LRP: IN VITRO AND IN VIVO ANALYSES
|
| Hilden I., Holm P.K., Karpf D.M., Østergaard H., Bolt G., Krogh-Meibom T., Kjalke M., Steenstrup T.D. |
| |
|
FACTOR VIII ASSAY DISCREPANCY IN TYPE 2N VWD IS REAGENT DEPENDANT
|
| Bowyer A.E., Cartwright I., Kitchen S., Makris M. |
| |
|
FACTOR VIII CONCENTRATES OF RECOMBINANT ORIGIN SHOW A HIGHER SUSCEPTIBILITY TO THROMBIN PROTEOLYSIS THAN PLASMA-DERIVED CONCENTRATES BUT NEARLY IDENTICAL INACTIVATION RATES BY ACTIVATED PROTEIN C
|
| Poetzsch B., Mueller J., Duecker I., Oldenburg J. |
| |
|
FACTOR VIIII INHIBITOR IN SEVERE HEMOPHILIA A TREATED WITH PD-FVIII CONCENTRATES
|
| Batorova A., Jankovicova D., Horvathova D. |
| |
|
FACTOR VON WILLEBRAND IN PATIENTS WITH METABOLIC SYNDROME
|
| Oganova E.G. |
| |
|
FACTOR XA OR THROMBIN: IS FACTOR XA A BETTER TARGET
|
| Ansell J. |
| |
|
FACTOR XA OR THROMBIN: IS THROMBIN A BETTER TARGET?
|
| Weitz J.I. |
| |
|
FACTOR XI (FXI) IS PRESENT IN ANTI-D PREPARATIONS AND CAN INDUCE AN INHIBITOR TO FXI IN PATIENTS WITH SEVERE FXI DEFICIENCY
|
| Zucker M., Zivelin A., Teitel J., Seligsohn U. |
| |
|
FACTOR XI DEFICIENCY IN SOUTHERN IRAN AND REVIEW OF LITERATURE
|
| Karimi M., Jafari H., Akbari A., Afrasiabi A., Dehbozorgian J., Ardeshiri R. |
| |
|
FACTOR XI DEFICIENCY: THREE NOVEL MUTATIONS IN IRANIAN PATIENTS
|
| Fard-Esfahani P., Rastegar Lari G., Ravanbod S., Mirkhani F., Rassoulzadegan M., Ala F. |
| |
|
FACTOR XI MEDIATES PLATELET LAMELLIPODIA FORMATION AND TETHERING AND ROLLING UNDER SHEAR CONDITIONS
|
| McCarty O.J.T., White T.C., Berny M.A., Melinte I.A., Tucker E.I., Swanson C.E., Robinson D.K., Mousa S.A., Gruber A. |
| |
|
FACTOR XI PHENOTYPE-GENOTYPE CORRELATIONS
|
| Zivelin A., Zucker M., Salomon O., Seligsohn U. |
| |
|
FACTOR XIA (FXIA) AND TISSUE FACTOR (TF) ACTIVITY IN PLASMA OF PATIENTS WITH CORONARY ARTERY DISEASE (CAD)
|
| Butenas S., Undas A., Gissel M.T., Mann K.G. |
| |
|
FACTOR XIA RESIDUES TYR143, GLU98, AND LYS192 ARE IMPORTANT FOR SUBSTRATE FACTOR IX (FIX) AND S-2366 CATALYSIS
|
| Miller T.N., Sinha D., Walsh P.N. |
| |
|
FACTOR XIII DEFICIENCY: SYMPTOMS, DIAGNOSIS AND LONG-TERM REPLACEMENT THERAPY
|
| Casais P., Meschengieser S.S., Grosso S.H., Sanchez-Luceros A., Blanco A.N., Lazzari M.A. |
| |
|
FACTOR XIII IS AN IMPORTANT MEDIATOR IN THE COAGULATING PLASMA INDUCED IL-8 PRODUCTION BY HUMAN LUNG EPITHELIAL CELLS
|
| Schouten M., von Eije K., van 't Veer C., van der Poll T. |
| |
|
FACTOR XIII PHARMACOKINETICS
|
| Alvarado L.R., Nakagawa P., Hsieh L.B., Nugent D.J. |
| |
|
FACTOR XIII VAL34LEU VARIANT PROTECTS AGAINST CORONARY ARTERY DISEASE: A META-ANALYSIS
|
| Vokó Z., Bereczky Z., Katona É., Ádány R., Muszbek L. |
| |
|
FACTOR XIIIA-V34L AND FACTOR XIIIB-H95R GENE VARIANTS AND SURVIVAL AFTER MYOCARDIAL INFARCTION
|
| Gemmati D., Federici F., Campo G., Serino M.L., Valgimigli M., Guardigli G., Ferraresi P., Bernardi F., Ferrari R., Scapoli G.L., Catozzi L. |
| |
|
FACTOR XII-MEDIATED CONTACT ACTIVATION OCCURS ON THE SURFACE OF THROMBIN RECEPTOR ACTIVATING PEPTIDE (TRAP)-ACTIVATED PLATELETS
|
| Bäck J., Sánchez J., Elgue G., Hamad O., Nilsson Ekdahl K., Nilsson B. |
| |
|
FACTORS AFFECTING THE FACTOR VIII:C REACTIVITY WHEN TESTED IN PURIFIED SYSTEMS WITH CHROMOGENIC ASSAYS
|
| Amiral J.J., Vissac A.M. |
| |
|
FACTORS INFLUENCING THE ANTI-PLATELET FACTOR 4/HEPARIN ANTIBODY (ANTI-PF4/H AB) IMMUNE RESPONSE: AN ANALYSIS OF FOUR RANDOMIZED CONTROLLED TRIALS (RCT'S) COMPARING ENOXAPARIN (ENOX) TO FONDAPARINUX (FONDA)
|
| Warkentin T.E., Cook R.J., Greinacher A., Marder V.J., Kelton J.G. |
| |
|
FAILURE OF IMMUNE TOLERANCE INDUCTION IN HAEMOPHILIA B PATIENTS WITH C, T 6460 NONSENSE MUTATION
|
| Rodriguez N.I., Hoots W., Brown D.L., Womack M., Cantini M., Escobar M.A. |
| |
|
FALSE UNCOAGULABLE PT-INR RESULTS
|
| Redaelli R., Corno A.R., Borroni L., Lavagni M.G., Somaini M.G., Caimi T.M., Baudo F., Morra E. |
| |
|
FAMILY HISTORY OF MYOCARDIAL INFARCTION (MI) IS AN INDEPENDENT RISK FACTOR FOR VENOUS THROMBOEMBOLISM (VTE). THE TROMS STUDY
|
| Braekkan S., Mathiesen E.B., Njolstad I., Wilsgaard T., Stormer J., Hansen J. |
| |
|
FAMILY HISTORY, DEEP VENOUS THROMBOSIS AND THROMBOPHILIA
|
| van Sluis G.L., Gibson N.S., Buller H.R., Gerdes V.E.A. |
| |
|
FCGAMMARII MEDIATES PLATELET AGGREGATION CAUSED BY DISINTEGRINS AND GPIIB/IIIA MONOCLONAL ANTIBODY, AP2
|
| Ho P.L., Chang C.H., Huang T.F. |
| |
|
FEMALE HEMOPHILIA A - TWO UNUSUAL CASES DUE TO SKEWED X-INACTIVATION
|
| Knobe K.E., Soller M.J., Sjörin E., Ljung R.C.R. |
| |
|
FERRIC CHLORIDE INDUCES VASCULAR INJURY AND THROMBOSIS BY OXIDATIVE INJURY TO RED BLOOD CELLS
|
| Woollard K.J., Sturgeon S., Chin-Dusting J., Jackson S. |
| |
|
FIBRIN A-ALPHA PEPTIDE MEDIATED DELIVERY OF BIOLOGICALLY ACTIVE PROTEINS
|
| Paton C.M., Guo Y., Kerschen E.J., Weiler H. |
| |
|
FIBRIN AND FIBRINOLYSIS IN INFECTION AND HOST DEFENSE
|
| Degen J.L., Bugge T.H., Goguen J.D. |
| |
|
FIBRIN D-DIMERS IS ASSOCIATED WITH PREVALENT CARDIOVASCULAR EVENTS IN THE MOLI-SANI STUDY
|
| Iacoviello L., Di Castelnuovo A., De Curtis A., Costanzo S., Arcari A., Centritto F., De Lucia F., Di Stefano I., di Giuseppe R., Magnacca S., Pampuch A., Persichillo M., Plescia E., Rago L., Silvestri C., Vohnout B., Zito F., de Gaetano G., Donati M.B. |
| |
|
FIBRIN DEPOSITION ACCELERATES NEUROVASCULAR DAMAGE AND NEUROINFLAMMATION IN MOUSE MODELS OF ALZHEIMER'S DISEASE
|
| Paul J., Melchor J., Strickland S. |
| |
|
FIBRIN GEL POROSITY RELATES TO GLYCOSYLATED HAEMOGLOBIN IN PATIENTS WITH TYPE 1 DIABETES
|
| Antovic A.M., Wallen N.H., Salomonsson A.C., Lins P.E., Adamson U., Jörneskog G. |
| |
|
FIBRIN GEL POROSITY: COMPARISON OF TWO LABORATORY ASSAYS
|
| Antovic A.M., Jörneskog G., Salomonsson A.C., Lins P.E., Adamson U., He S., Wallen N.H. |
| |
|
FIBRIN GENERATION IS NOT SUPPRESSED IN PATIENTS WARFARINISED FOR VENOUS THROMBOEMBOLISM (VTE)
|
| Curnow J.L., Morel-Kopp M.C., Aboud M., Ward C.M. |
| |
|
FIBRIN MONOMER BY A QUANTITATIVE ASSAY IN PATIENTS WITH DISSEMINATED INTRAVASCULAR COAGULATION
|
| Mathonnet F.T., Tetegan M., de Jonghe B., Uzan M., Fischer C., Coltat J., Outin H., Giudicelli Y. |
| |
|
FIBRIN-MEDIATED THROMBUS FIXATION TO ENDOTHELIUM LEADS TO MONOLAYER DISRUPTION AFTER SHEAR INDUCED THROMBUS DISLODGEMENT
|
| Reininger A.J., Korndörfer M., Wurzinger L.J. |
| |
|
FIBRINOGEN AND FIBRIN INDUCE SYNTHESIS OF PROINFLAMMATORY CYTOKINES FROM PERIPHERAL BLOOD MONONUCLEAR CELLS
|
| Jensen T., Kierulf P., Sandset P.M., Klingenberg O., Joø G.B., Godal H.C., Skjønsberg O.H. |
| |
|
FIBRINOGEN HAPLOTYPES AND PLASMA LEVELS SHOW INDEPENDENT ASSOCIATION TO ISCHEMIC STROKE
|
| Jood K., Danielson J., Ladenvall C., Blomstrand C., Jern C. |
| |
|
FIBRINOGEN SYNTHESIZED BY CANCER CELLS AUGMENTS THE PROLIFERATIVE EFFECT OF FGF-2
|
| Sahni A., Simpson-Haidaris P.J., Sahni S.K., Vaday G.G., Francis C.W. |
| |
|
FIBRINOGEN THR312ALA BUT NOT FXIIIA VAL34LEU AND FXIIIB HIS95ARG POLYMORPHISMS ASSOCIATED WITH THAI DEEP VENOUS THROMBOSIS
|
| Komanasin N., Angchaisuksiri P., Mongkolwongroj P., Puntumetakul M., Aryuchai K. |
| |
|
FIBRINOGEN VARIANT BD432A: NEW INSIGHTS ON THE ROLE OF "B:b" INTERACTIONS IN FIBRIN POLYMERIZATION
|
| Bowley S.R., Gorkun O.V., Lord S.T. |
| |
|
FIBRINOLYSIS, INFLAMMATION, AND REGULATION OF THE PLASMINOGEN ACTIVATING SYSTEM
|
| Medcalf R.L. |
| |
|
FIBRINOLYTIC CAPACITY OF CORD PLASMA COMPARED TO ADULT OVER VARIOUS CONCENTRATIONS OF TPA
|
| Mitchell L.G., Bajzar L., Rahal A. |
| |
|
FIBRINOLYTIC DEFICIT CONTRIBUTES TO THE THROMBOTIC COMPLICATIONS IN END STAGE RENAL DISEASE. PROFILING OF PLASMINOGEN ACTIVATOR INHIBITOR, TISSUE PLASMINOGEN ACTIVATOR, FACTOR XIII THROMBIN ACTIVATABLE FIBRINOLYTIC INHIBITOR, AND ALPHA2 ANTIPLASMIN
|
| Patel C., Bajwa R.S., Iqbal O., Cunanan J., Hoppensteadt D., Kujawski M., Fareed J., Bansal V. |
| |
|
FIBRINOLYTIC INHIBITORS LEVELS AND POLYMORPHISMS IN BEHCET DISEASE. THEIR RELATIONSHIP WITH VENOUS THROMBOSIS
|
| Ricart J.M., Ramon L.A., Vaya A., España F., Santaolaria M., Todoli J., Castello R., Fontcuberta J., Estelles A. |
| |
|
FIBRINOLYTIC PARAMETERS IN CHILDREN WITH NON-CATHETER RELATED DEEP VENOUS THROMBOSIS
|
| Kupesiz O.A., Rajpurkar M.A., Chitlur M.B., Lusher J.M., Hollon W., Warrier I. |
| |
|
FIBRINOLYTIC SYSTEM COMPONENTS IN RABBIT TEARS AFTER CHEMICAL BURN OF CORNEA
|
| Mukhametova L.I., Aisina R.B., Gulin D.A., Beznos O.V., Stolyarova E.P., Chesnokova N.B. |
| |
|
FINAL ANALYSIS OF A PROSPECTIVE-MULTICENTRE STUDY TO EVALUATE EFFICACY AND SAFETY OF A TRIPLE-SECURED VON WILLEBRAND FACTOR (VWF)
|
| Federici A.B., Borel-Derlon A., Roussel-Robert V., Goudemand J., Lee C.A., Scharrer I., Rothschild C., Berntorp E., Tellier Z., Bridey F., Mannucci P.M., French VWF SD-35-DH Study Group |
| |
|
FINAL RESULTS OF A FEASIBILITY STUDY ON AN ELECTRONIC MONITORING SYSTEM IN HEMOPHILIA CARE
|
| Mondorf W., Pollmann H. |
| |
|
FINAL RESULTS OF A PROSPECTIVE-MULTICENTRE STUDY TO EVALUATE PHARMACOKINETICS, EFFICACY AND SAFETY OF A SOLVENT-DETERGENT TREATED AND 15 NANOMETER-FILTERED PLASMA-DERIVED FACTOR VIII
|
| Rothschild C., Windyga J., Peerlinck K., Hermans C., Tellier Z., Souquieres M., Bridey F., French FVIII SD-35-15 Study Group |
| |
|
FIRST EXPERIENCE WITH IMMUNE TOLERANCE INDUCTION IN HAEMOPHILIA A PATIENTS WITH INHIBITOR TO FACTOR VIII IN RUSSIA
|
| Zozulya N.I., Plyushch O.P., Severova T.V. |
| |
|
FIRST EXPERIENCE WITH THROGA (THROMBIN GENERATION ASSAY) IN IDENTIFICATION OF HYPER- AND HYPOCOAGULABILITY
|
| Nowak G., Wiesenburg A. |
| |
|
FIRST INTERIM ANALYSIS OF SEVEN BLEEP REGISTRY FOCUSED ON EFFICACY AND SAFETY OF THE TREATMENT WITH RFVIIA IN MASSIVE HAEMORRHAGE IN CHILDREN
|
| Blatny J., Mathew P., Puetz J. |
| |
|
FISH INTAKE AND LPA 93CT POLYMORPHISM: GENE-ENVIRONMENT INTERACTION IN MODULATING LIPOPROTEIN (A) CONCENTRATIONS
|
| Sofi F., Fatini C., Sticchi E., Lenti M., Gori A., Giusti B., Fedi S., Casini A., Abbate R., Gensini G. |
| |
|
FIVE NOVEL MUTATIONS IN F13B GENE RESULTING IN MILD FXIII DEFICIENCY
|
| Ivaskevicius V., Rott H., Trobisch H., Halimeh S., Scharrer I., Krause M., Seifried E., Oldenburg J. |
| |
|
FIVE PROTHROMBOTIC POLYMORHISMS AND VENOUS THROMBOEMBOLISM
|
| García-Raso A., Santos A.B., Moreno V.P., Raquel M., Dolores S., Llamas P. |
| |
|
FLAVONOIDS INHIBIT PLATELET ADHESION AND AGGREGATION UNDER FLOW: BLOCKADE OF TXA2 RECEPTORS IN PLATELET RICH PLASMA
|
| Navarro-Núñez L., Palomo M., Lozano M., Martínez C., Pérez-Ceballos E., Vicente V., Castillo J., Escolar G., Díaz-Ricart M., Rivera J. |
| |
|
FLK-1-BASED DNA VACCINATION REDUCES ATHEROSCLEROTIC LESION GROWTH IN HYPERLIPIDEMIC MICE
|
| Petrovan R.J., Curtiss L.K. |
| |
|
FLOVAGATRAN (TGN 255), BIVALIRUDIN AND MELAGATRAN - DIFFERENTIAL PHARMACOLOGICAL EFFECTS ON THROMBIN GENERATION
|
| Chander C.L., Beck R., Blackney M., Chahwala S.B. |
| |
|
FLOW CYTOMETRIC ANALYSIS OF VASP PHOSPHORYLATION IN PLATELETS TREATED WITH THE ACTIVE METABOLITE OF PRASUGREL, A P2Y12 ADP RECEPTOR ANTAGONIST
|
| Asai F., Ogawa T., Yokouchi Y., Niitshu Y., Jakubowski J.A., Sugidachi A. |
| |
|
FLOW-INDUCED THROMBUS FORMATION ON IMMOBILIZED COLLAGEN RECEPTOR-BINDING PEPTIDES
|
| Munnix I.C.A., Gilio K., Raynal N., Feijge M.A.H., Fletcher J., Siljander P.R.M., Farndale R.W., Heemskerk J.W.M. |
| |
|
FLUID LOSS, COAGULATION ACTIVATION AND AIR TRAVEL
|
| Schreijer A.J.M., Cannegieter S.C., Caramella M., Meijers J.C.M., Krediet R.T., Simons R.M., Büller H.R., Rosendaal F.R. |
| |
|
FLUVASTATIN INHIBITS REGULATED SECRETION OF ENDOTHELIAL CELL VON WILLEBRAND FACTOR IN RESPONSE TO DIVERSE SECRETAGOGUES
|
| Fish R.J., Yang H., Viglino C., Schorer R., Dunoyer-Geindre S., Kruithof E.K.O. |
| |
|
FOLIC ACID ADMINISTRATION AND PLATELET ACTIVATION AT THE SITE OF MICROVASCULAR INJURY IN SUBJECTS WITH ELEVATED TOTAL HOMOCYSTEINE
|
| Undas A., Stepien E., Plicner D., Zielinski L., Pazdan A., Tracz W. |
| |
|
FONDAPARINUX 1.5 MG ONCE DAILY IN THE PROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE): EFFICACY AND SAFETY IN RENALLY-IMPAIRED PATIENTS FROM A DOSE-RANGING STUDY IN MAJOR ORTHOPEDIC SURGERY
|
| Turpie A.G. |
| |
|
FONDAPARINUX IN THE TREATMENT OF SYMPTOMATIC, ISOLATED SUPERFICIAL THROMBOPHLEBITIS (ST): THE CALISTO TRIAL
|
| Decousus H., Leizorovicz A., Prandoni P. |
| |
|
FONDAPARINUX IS A SAFE AND EFFECTIVE ALTERNATIVE ANTICOAGULANT IN PREGNANT WOMEN WITH INTOLERANCE TO LOW-MOLECULAR- WEIGHT HEPARINS AND HEPARINOIDS
|
| Gerhardt A., Stockschlaeder M., Araba F., Scharf R.E., Zotz R.B. |
| |
|
FONDAPARINUX IS SAFER THAN ENOXAPARIN IN ELDERLY PATIENTS WITH NON-ST ELEVATION ACUTE CORONARY SYNDROMES: A SUBANALYSIS OF OASIS-5
|
| Bassand J., Mehta S.R. |
| |
|
FONDAPARINUX REDUCED MAJOR BLEEDING VERSUS ENOXAPARIN IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING EARLY INVASIVE MANAGEMENT EVEN IN THE CONTEXT OF TRANS-RADIAL CORONARY INTERVENTION: INSIGHTS FROM OASIS-5
|
| Hamon M., Mehta S.R. |
| |
|
FORMATION OF SUBPOPULATIONS WITH DIFFERENT PHOSPHATIDYLSERINE EXPRESSION DURING THROMBIN-STIMULATED PLATELET ACTIVATION IS CONTROLLED BY ALPHA-GRANULE ADP SECRETION
|
| Panteleev M.A., Ataullakhanov F.I. |
| |
|
FOUR NOVEL CAUSATIVE MUTATIONS IDENTIFIED IN THE PROS1 GENE OF JAPANESE DEEP VEIN THROMBOSIS PATIENTS WITH PROTEIN S DEFICIENCY
|
| Sanda N., Fujimori Y., Kashiwagi T., Yamada T., Okumura K., Takagi A., Murate T., Iwasaki T., Katsumi A., Yamamoto K., Matsushita T., Naoe T., Saito H., Kojima T. |
| |
|
FRACTALKINE RECEPTOR CX3CR1 EXPRESSION IN PLATELETS FROM PATIENTS WITH CARDIOVASCULAR DISEASE
|
| Klinkhardt U., Meyer Dos Santos S., Gossmann J., Harder S. |
| |
|
FREE PROTEIN S LEVELS DURING PREGNANCY
|
| Martinez P.A., Reimer E., Gilio J. |
| |
|
FREQUENCIES OF CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5, MDR1 ALLELIC VARIANTS IN PATIENTS WITH DIFFERENT ACENOCOUMAROL DOSE REQUIREMENTS
|
| Saraeva R., Paskaleva I., Doncheva E., Eap C., Ganev V. |
| |
|
FREQUENCY AND TIME OF ONSET OF ACUTE MYOCARDIAL INFARCTION IN SUDDEN UNEXPECTED DEATHS IN A FORENSIC AUTOPSY MATERIAL
|
| Mortensen E., Rognum T.O., Straume B., Jørgensen L. |
| |
|
FREQUENCY OF "SPECIAL POPULATION" CHARACTERISTICS IN VENOUS THROMBOEMBOLISM PATIENTS IN CLINICAL PRACTICE: EFFECT ON PATIENT MANAGEMENT
|
| Cook L., Kahn S.R., Goodwin J., Kovacs M.J. |
| |
|
FREQUENCY OF F II20210A IN WOMEN WITH VENOUS THROMBOEMBOLISM IN ASSOCIATION WITH ORAL CONTRACEPTIVE USE
|
| Dulicek P., Maly J.J.M., Vrbacky F.F.V., Beranek M.M.B., Pecka M.M.P. |
| |
|
FRESH FROZEN PLASMA DOES NOT ATTENUATE COAGULATION ACTIVATION AFTER NEONATAL CARDIOPULMONARY BYPASS
|
| Långström S., Rautiainen P., Mildh L., Peltola K., Wartiovaara-Kautto U., Heikinheimo M., Petäjä J. |
| |
|
FROM HEMATOPOIETIC STEM CELLS TO PLATELETS
|
| Yun-Hua C., Bluteau D., Debili N., Vainchenker W. |
| |
|
FUNCTIONAL ANALYSES OF THE LEU752ARG AND GLN891STOP ASSOCIATED WITH GLANZMANN THROMBASTHENIA
|
| Jin P., Wang X., Ding Q., Wang H. |
| |
|
FUNCTIONAL ANALYSIS OF ANTI-GPVI MONOCLONAL ANTIBODIES WITH DISTINCT BINDING SITES
|
| Matsumoto Y., Takizawa H., Gong X., Concepcion A., Tandon N.N., Kambayashi J. |
| |
|
FUNCTIONAL ANALYSIS OF HUMAN PLATELETS IN NOD/SCID MICE
|
| Salles I.I., De Meyer S.F., Reynaert A., Brunaud C., Vanhoorelbeke K., Deckmynon H. |
| |
|
FUNCTIONAL ANALYSIS OF SNPS SPECIFIC FOR HAPLOTYPE 1 (H1) OF THE GENE CODING FOR THE ENDOTHELIAL PROTEIN C RECEPTOR (EPCR)
|
| Medina P., España F., Vos H.L., Bertina R.M. |
| |
|
FUNCTIONAL CHARACTERISATION OF HAPLOTYPIC VARIATION IN THE GP6 GENE PROMOTER
|
| Sivasubramaniam M., Winship P.R., Daly M.E. |
| |
|
FUNCTIONAL CHARACTERIZATION OF PROLINE-RICH GLA PROTEINS (PRGPS) 1 AND 2
|
| Kulman J.D., Harris J.E., Mize G.J., Davie E.W. |
| |
|
FUNCTIONAL CHARACTERIZATION OF STRUCTURAL EPITOPES IN THE C2 DOMAIN OF FACTOR VIII
|
| Meeks S.L., Healey J.F., Barrow R.T., Parker E.T., Lollar P. |
| |
|
FUNCTIONAL COAGULATION ANALYSIS IN PATIENTS WITH BLOOD COAGULATION DISORDERS OR HYPERCOAGULABILITY: SIGNIFICANCE OF WHOLE BLOOD ROTATION THROMBELASTOGRAPHY IN COMPARISON WITH CONVENTIONAL BLOOD COAGULATION ANALYSIS
|
| Knoebl P.N., Kopp S., Mladenov M., Stiegler G., Quehenberger P. |
| |
|
FUNCTIONAL ELISA OF VON WILLEBRAND FACTOR (VWF) ACTIVITY USING HIS-TAGGED INCREASE-OF-FUNCTION RECOMBINANT GPIB BOUND TO NICKEL CHELATE PLATES
|
| Hui S.R., Biswas T.K., Miller J.L. |
| |
|
FUNCTIONAL IN VITRO CHARACTERIZATION OF A NOVEL ADAMTS13 MUTATION (R1095W) AND POLYMORPHISM (S903L)
|
| Feys H.B., Liu F., De Maeyer B., Dong N., Vandeputte N., Deckmyn H., Vanhoorelbeke K., Ruan C. |
| |
|
FUNCTIONAL REGULATION OF TFPI IN LIPID RAFTS/CAVEOLAE
|
| Lupu C., Lupu F. |
| |
|
FUNCTIONAL REGULATION OF VON WILLEBRAND FACTOR ON THE FORMATION OF PLATELET THROMBI UNDER BLOOD FLOW CONDITION BY ITS SPECIFIC CLEAVING PROTEASE OF ADAMTS13
|
| Tamura N., Soejima K., Moriguchi-Goto S., Yamashita A., Asada Y., Goto S. |
| |
|
FUNCTIONAL STRUCTURE OF THE SOMATOMEDIN B DOMAIN OF VITRONECTIN
|
| Zhou A. |
| |
|
FUNCTIONAL VARIABILITY OF PLATELET RESPONSE TO CLOPIDOGREL CORRELATES WITH P2Y12 RECEPTOR OCCUPANCY
|
| Bal dit Sollier C., Berge N., Boval B., Hovsepian L., Drouet L. |
| |
|
FUNCTIONALITY OF THE VASOPRESSIN 2 RECEPTOR VARIATION G12E AS MODIFIER OF VON WILLEBRAND FACTOR AND FACTOR VIII LEVELS
|
| Nossent A.Y., Robben J.H., Deen P.M.T., Rosendaal F.R., Bertina R.M., Eikenboom J.C.J. |
| |
|
FURTHER CHARACTERISATION OF ADAMTS13 INACTIVATION BY THROMBIN
|
| Lam J.K., Chion C.K.N.K., Zanardelli S., Lane D.A., Crawley J.T.B. |
| |
|
FURTHER EVIDENCE FOR TWO FUNCTIONAL FORMS OF PROTHROMBINASE
|
| Kim P.Y., Nesheim M.E. |
| |
|
FURTHER VALIDATION AND SIMPLIFICATION OF THE WELLS CLINICAL DECISION RULE IN PULMONARY EMBOLISM
|
| Gibson N.S., Sohne M., Kruip M.J.H., Tick L.W., Gerdes V.E., Bossuyt P.M., Wells P.S., Buller H.R. |
| |
|
FV LEIDEN, FII G20210A AND MTHFR T677T GENOTYPES: IS THEIR EVALUATION A USEFUL TOOL IN THE ETIOLOGICAL APPROACH OF THE EARLY RECURRENT PREGNANCY LOSSES IN THE GREEK POPULATION?
|
| Mougiou A., Karakantza M., Androutsopoulos G., Decavalas G., Zoumbos N. |
| |
|
FV LEIDEN, THE APOE GENOTYPE AND OTHER GENE POLYMORPHISMS IN PATIENTS UNDERGOING CARDIAC SURGERY
|
| Bach J., Kammerer I., Isgro F., Saggau W., Hellstern P. |
| |
|
FVII ACTIVITY AND R353Q POLYMORPHISM IN ASIAN INDIAN FAMILIES WITH CORONARY ARTERY DISEASE
|
| Shanker J., Ganapathy P., Rao V.S., Natesha B.K., Mukherjee M., Kakkar V.V. |
| |
|
FVIII CONCENTRATES OF RECOMBINANT ORIGIN SHOW A HIGHER THROMBIN SENSITIVITY THAN PLASMA-DERIVED FVIII CONCENTRATES BUT NEARLY IDENTICAL APC-MEDIATED INACTIVATION KINETICS
|
| Poetzsch B., Mueller J., Dücker I., Oldenburg J. |
| |
|
FVIII/VWF CONCENTRATE FOR IMMUNE TOLERANCE INDUCTION (ITI) IN ITALIAN HAEMOPHILIACS WITH NEGATIVE PREDICTORS OF ITI RESPONSE
|
| Coppola A., Mancuso G., Morfini M., Santagostino E., Biasoli C., Schiavulli M., Scaraggi F.A. |
| |
|
FVIII-SPECIFIC MEMORY B CELLS IN PATIENTS WITH HEMOPHILIA A
|
| van Helden P.M.W., Kaijen P.H.P., van Haren S.D., Dohmen S.E., Mul F.P.J., Fijnvandraat K., van den Berg M.H., Voorberg J. |
| |
|
FX DEFICIENCY: CHARACTERISTICS AND TREATMENT OUTCOME OF SEVEN CASES
|
| Salcioglu Z., Aydogan G., Akici F., Baslar Z., Aktay Ayaz N., Sayilan Sen H.H.S., Yanilmaz O., Aldemir H. |
| |
|
FXI/ADAMTS13 COMPLEX IN PLASMA
|
| Starke R.D., Lawrie A., Scully M., Machin S., Mackie I. |
| |
|
FXIII VARIANTS WITH ALTERED THROMBIN ACTIVATION RATES
|
| Andersen M.D., Kjalke M., Bang S., Lautrup-Larsen I., Becker P., Andersen A.S., Diers I.V., Røjkjær R., Olsen O.H., Stennicke H.R. |
| |
